CHEM2052 Tutorial Example4

From Proteopedia

(Difference between revisions)
Jump to: navigation, search
Current revision (08:51, 13 August 2014) (edit) (undo)
 
(16 intermediate revisions not shown.)
Line 3: Line 3:
== '''Chem2052: Example 4 - Renin''' ==
== '''Chem2052: Example 4 - Renin''' ==
-
The spinning structure you initially view on this page is an enzyme called Renin. Renin is an '''aspartyl protease''', like other proteases Renin cleaves peptides.
+
The spinning structure you initially view on this page is a protease called '''Renin''' (also known as '''angiotensinase'''). Renin is an '''aspartyl protease''', which cleaves a particular peptide called angiotensinogen. Although this enzyme functions as a monomer the crystal structure obtained is a dimer and this is what you can see here. In the following representations one of the sub-units has been removed to represent the protein in its natural state.
-
== Background ==
+
== '''Background''' ==
-
In later lecture we will look a little more closely at '''Renin''' (also known as '''angiotensinase'''). This enzyme is involved in a biological pathway leading to elevation of blood pressure, which can be beneficial in many ways. However if this process has become overactive, hypertension (high blood pressure) can result. Hypertension leads to cardiovascular disease which is the leading cause of death globally. The World Health Organisation states "An estimated 17.3 million people died from cardiovascular disease in 2008, representing 30% of all global deaths" see the following web page if you want to know more: [http://www.who.int/mediacentre/factsheets/fs317/en/].
+
In later lecture we will look a little more closely at '''Renin'''. This enzyme is involved in a biological pathway leading to elevation of blood pressure, which can be beneficial in many ways. However if this process has become overactive, hypertension (high blood pressure) can result. Hypertension leads to cardiovascular disease which is the leading cause of death globally. The World Health Organisation states "An estimated 17.3 million people died from cardiovascular disease in 2008, representing 30% of all global deaths" see the following web page if you want to know more: [http://www.who.int/mediacentre/factsheets/fs317/en/ Cardiovascular disease facts WHO].
Since the 1970s scientists have been trying to modulate the action of renin by blocking the active site of the enzyme and preventing its function, hence lowering blood pressure. Aliskerin is the only renin inhibitor in clinical use today [http://en.wikipedia.org/wiki/Renin_inhibitor Renin information Site]. However there is still interest in developing new, improved inhibitors. This question looks at a renin inhibitor identified through research at Pfizer.<ref>PMID:17574423</ref>
Since the 1970s scientists have been trying to modulate the action of renin by blocking the active site of the enzyme and preventing its function, hence lowering blood pressure. Aliskerin is the only renin inhibitor in clinical use today [http://en.wikipedia.org/wiki/Renin_inhibitor Renin information Site]. However there is still interest in developing new, improved inhibitors. This question looks at a renin inhibitor identified through research at Pfizer.<ref>PMID:17574423</ref>
-
== '''Active Sites''' ==
+
== '''Active Site''' ==
-
This representation illustrates the active site catalytic residues of Renin.
+
This representation illustrates the <scene name='59/596437/Renin_catalytic_residues/2'>active site catalytic residues</scene> of Renin. Consider the mechanism of the enzymatic cleavage of the natural peptide substrate by the catalytic residues [http://www.cambridgemedchemconsulting.com/resources/hit_identification/aspartic_protease_inhibitors.html you will find it here]. Identify the structure of the transition state. In later lectures we will see how knowledge of this transition state can be used to design very effective enzyme inhibitors which mimic this structure, as you will find out, these are (not surprisingly) called "transition state" inhibitors. But for now though we will focus on the Pfizer inhibitor.
-
<scene name='55/559112/Renin_catalytic_residues/1'>Renin Catalytic Residues</scene>
+
-
<scene name='55/559112/Renin_catalytic_residues/1'>Renin Catalytic Residues</scene>
+
-
'''Serine proteases''' account for over one-third of all known proteolytic enzymes <ref>PMID:17991683</ref>,<ref name="DiCera">PMID:19180666</ref>. Within the diverse collection of serine proteases, the most famous members are trypsin, chymotrypsin and elastase. Aside from their key roles in digestion (and other physiological processes) <ref name ="DiCera"/>, the unique specificities of these enzymes make them useful tools in biochemistry and molecular biology to ascertain protein sequences.
+
== '''Inhibition of Renin''' ==
-
Looking at the structures below, it is apparent that these three enzymes have similar folds. This conservation of tertiary structure is due to extensive similarities at the level of primary amino acid sequence. However, there are small differences in amino acid sequence among the proteins, which are reflected in their different specificities. Each protein cleaves the peptide backbone after (or on the carbonyl side) of a specific type of sidechain. After examining the molecular basis for these functional similarities and differences, you will hopefully see why serine proteases are a classic example of how '''''structure dictates function'''''!
+
This scene shows the <scene name='55/559112/Renin_catalytic_residues/1'>active site of renin with the Pfizer inhibitor bound</scene>. Which part of the inhibitor binds to the catalytic residues of the active site?
-
*<scene name='User:Amy_Kerzmann/Sandbox_5/New_chymotrypsin-triad/2'>Chymotrypsin</scene>
+
== '''Active Site Interactions''' ==
-
*<scene name='User:Amy_Kerzmann/Sandbox_5/New_trypsin-wt-triad/4'>Trypsin</scene>
+
-
*<scene name='User:Amy_Kerzmann/Sandbox_5/New_elastase-triad/3'>Elastase</scene>
+
 +
This inhibitor does not just bind to the catalytic residues there are many other amino acids at the active site of the enzyme. First predict possible interaction types you would expect with this structure. Then look at the 2-dimensional "map" of the active site provided on your tutorial sheet and compare this to the 3-dimensional representations here.
 +
This view shows the amino acid residues on the <scene name='59/596437/Renin_interactions_rhs/2'>right hand side</scene> of your "map". You should notice that these amino acids are fairly hydrophobic and interact with the hydrophobic parts of the inhibitor. If you prefer to view the structure where the inhibitor atoms are colour coded you will <scene name='59/596437/Renin_interactions_rhs_again/1'>find it here. </scene>
 +
Similarly this view shows the amino acid residues on the
 +
<scene name='59/596437/Lhs_aminoacids_representation/2'>left hand side</scene> of your "map". Again you can view this with the atoms of the inhibitor colour coded
 +
<scene name='59/596437/Lhs_aminoacids_representation/3'>find it here</scene>.
- 
- 
- 
-
== Active Site and Mechanism ==
 
- 
-
== Inhibitors ==
 
- 
-
== Structural highlights ==
 
- 
-
This is a sample scene created with SAT to <scene name="/12/3456/Sample/1">color</scene> by Group, and another to make <scene name="/12/3456/Sample/2">a transparent representation</scene> of the protein. You can make your own scenes on SAT starting from scratch or loading and editing one of these sample scenes.
 
- 
-
</StructureSection>
 
== References ==
== References ==
<references/>
<references/>

Current revision

CHEM2052_Tutorial_Example4

Renin (PDB code 2i4q)

Drag the structure with the mouse to rotate

Proteopedia Page Contributors and Editors (what is this?)

Avril Robertson

Personal tools